Processing...
Clinical Trials for Stomach Cancer
Search
Search
There are 157 active trials for advanced/metastatic stomach cancer.
Click on a trial to see more information.
157 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.
ClinicalTrials.gov ID: NCT07080242
TrialFetch AI summary: Adults with peritoneal-only metastatic gastric or GEJ adenocarcinoma (ECOG 0–2) receive standard systemic chemotherapy followed by preoperative laparoscopic HIPEC, then gastrectomy with cytoreductive surgery and intraoperative HIPEC. Aims to improve progression-free and overall survival in patients without extra-peritoneal metastases.
ClinicalTrials.gov ID: NCT07178808
TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults (ECOG 0–1) with refractory/recurrent locally advanced or metastatic solid tumors—particularly tissue factor–expressing cancers such as HNSCC, NSCLC, esophagogastric, colorectal, pancreatic ductal adenocarcinoma, cervical, endometrial, or urothelial carcinoma—after appropriate prior systemic therapy (prior-line limits vary by study part) are eligible. Treatment is STRO-004, a tissue factor–targeting antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given as monotherapy with dose escalation/expansion or combined with pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT07227168
TrialFetch AI summary: Enrolls adults with relapsed/refractory locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation (ECOG 0–1, measurable disease) after progression on, intolerance of, or ineligibility for standard approved therapies. Patients receive oral once-daily PLX-61639, a SMARCA2 targeted protein degrader (synthetic-lethal strategy in SMARCA4-deficient tumors; DCAF16-linked, proteasome-mediated SMARCA2 degradation).
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Enrolling adults with unresectable locally advanced or metastatic solid tumors (often GI) that have progressed on or lack standard options, ECOG 0–1, with measurable disease and available tissue/biopsy for CDH17 testing. Patients receive open-label MRG007 (ARR-217), a CDH17-targeted antibody–drug conjugate delivering an exatecan-based topoisomerase I inhibitor payload, in dose escalation followed by confirmation/expansion.
ClinicalTrials.gov ID: NCT07066657
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198